Comparative Pharmacology
Head-to-head clinical analysis: DEXASPORIN versus ZYLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXASPORIN versus ZYLET.
DEXASPORIN vs ZYLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
Loteprednol etabonate is a corticosteroid that inhibits phospholipase A2 activity, reducing prostaglandin and leukotriene synthesis. Tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
One to two drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours. In severe cases, every 1 to 2 hours for the first 24 to 48 hours.
None Documented
None Documented
3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min)
ZYLET: not applicable (fixed-dose combination); Loteprednol: 2-3 hours; Tobramycin: 2-3 hours. Clinical context: no accumulation with qid dosing.
Renal excretion (80-90% unchanged), biliary/fecal (10-20%)
Renal (30% unchanged), biliary/fecal (70% as metabolites)
Category C
Category C
Corticosteroid/Antibiotic Combination
Corticosteroid/Antibiotic Combination (Ophthalmic)